Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
COGTthis companyCogent Biosciences, Inc.	$32.94	-17.41×	8.99×	0×	-17.61×	-99.0%	0.0%	0.0%	0.0%	-51.7%	-38.1%	-4.7%	0.4×	0.18×	-108.87×	14.23×	0.0%	2	7.51	1	C-
AVBPArriVent BioPharma, Inc.	$13.98	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
IDYAIDEAYA Biosciences, Inc.	$31.52	-27.01×	2.99×	13.99×	-19.22×	-438.0%	-43.9%	-72.8%	-52.0%	-11.1%	-15.2%	-2.4%	0.03×	0.55×	0×	11.34×	0.0%	1	14.74	2	C
INCYIncyte Corporation	$120.30	14.99×	3.73×	3.75×	9.23×	-2.4%	92.8%	26.1%	25.0%	24.9%	20.6%	7.0%	0.01×	-1.72×	553.04×	3.32×	0.0%	6	10.87	3	B+
KURAKura Oncology, Inc.	$7.63	-3.27×	5.23×	13.5×	-2.84×	72.0%	99.9%	-449.9%	-412.9%	-160.0%	-48.8%	-7.8%	0.12×	0.47×	-200.81×	6.06×	0.0%	3	-2.79	2	C
MAZEMaze Therapeutics, Inc.	$34.30	-13.58×	5.02×	0×	-12.54×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.07×	1.29×	0×	15.5×	0.0%	3	11.54	2	C
Peer median	—	-4.66×	3.73×	3.75×	-4.38×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.03×	0.47×	0×	11.34×	0.0%	3	11.54	2	—